Antibodies against complement system in SLE and their potential diagnostic utility

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A00009789" target="_blank" >RIV/61989592:15110/09:00009789 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Antibodies against complement system in SLE and their potential diagnostic utility

Popis výsledku v původním jazyce

SLE is characterized by overproduction of various types of antibodies. Under certain circumstances, antibodies aiming some of the neoepitopes of the complement system can be seen. Neoepitopes are not present in the native proteins, but they appear afterthe structural change of the complement system. One of these antibodies binds the activated product C3 called iC3b+ however, its possible part in the pathogenesis of a disease is unknown. Some of the antibodies to the component of the complement system are more significant. One of them is the C3 nephritic factor connected with partial lipodystrophy and with a certain form of mesangial glomerulonephritis. This factor also rarely appears in patients with SLE. Another antibody targets the C1 inhibitor andappears in some patients with lymphomas. Anti-C1q antibodies are present in approximately one third of the patients with lupus, who often have high clinical activity of the disease, and particularly, renal involvement. In the presence of

Název v anglickém jazyce

Antibodies against complement system in SLE and their potential diagnostic utility

Popis výsledku anglicky

SLE is characterized by overproduction of various types of antibodies. Under certain circumstances, antibodies aiming some of the neoepitopes of the complement system can be seen. Neoepitopes are not present in the native proteins, but they appear afterthe structural change of the complement system. One of these antibodies binds the activated product C3 called iC3b+ however, its possible part in the pathogenesis of a disease is unknown. Some of the antibodies to the component of the complement system are more significant. One of them is the C3 nephritic factor connected with partial lipodystrophy and with a certain form of mesangial glomerulonephritis. This factor also rarely appears in patients with SLE. Another antibody targets the C1 inhibitor andappears in some patients with lymphomas. Anti-C1q antibodies are present in approximately one third of the patients with lupus, who often have high clinical activity of the disease, and particularly, renal involvement. In the presence of

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8406" target="_blank" >NR8406: Prognostický význam přítomnosti hypokomplementemie pro typ a klinickou manifestaci lupusové glomerulonefritidy</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Rheumatology Reviews

ISSN

1573-3971

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—